rapid
fatal
evolut
coronaviru
advanc
lung
cancer
patient
long
time
respons
nivolumab
lucia
bonomi
laura
ghilardi
ermenegildo
arnoldi
carlo
alberto
tondini
anna
cecilia
bettini
oncolog
unit
asst
ospedal
papa
giovanni
xxiii
bergamo
correspond
author
lucia
bonomi
lbonomi
author
declar
follow
potenti
conflict
interest
respect
research
authorship
andor
public
articl
lucia
bonomi
anna
cecilia
bettini
laura
ghilardi
receiv
bm
fund
reimburs
attend
symposia
coronaviru
pandem
diseas
itali
first
case
document
end
januari
show
dramat
spread
liang
colleagu
report
increas
risk
cancer
patient
poorer
prognosi
without
cancer
present
case
rapid
fatal
evolut
patient
metastat
lung
cancer
partial
remiss
immunotherapi
sinc
march
yearold
male
patient
present
emerg
depart
short
breath
fever
mental
confus
hemogasanalysi
show
hypoxia
laboratori
test
reveal
normal
leukocyt
lymphopenia
elev
creactiv
protein
transaminas
lactat
deidrogeneas
chest
xray
show
reticularinterstiti
addens
find
nasal
swab
posit
nivolumab
checkpoint
inhibitor
without
advers
event
hold
partial
respons
last
ct
scan
perform
februari
describ
stabl
diseas
march
admit
infecti
diseas
unit
start
empir
antibiot
treatment
oxygen
therapi
reservoir
mask
lmin
sedat
agit
reason
never
receiv
prescrib
lopinavirritornavir
hydroxychloroquin
patient
rapid
worsen
condit
die
march
specif
therapeut
agent
coronaviru
infect
world
health
organ
suggest
guidanc
manag
sever
patient
treat
empir
antimicrobi
oxygen
therapi
symptomat
treatment
emerg
evid
suggest
patient
sever
cours
may
respond
infect
cytokin
storm
biopsi
sampl
autopsi
patient
die
sever
histolog
examin
show
bilater
diffus
alveolar
damag
cellular
fibromyxoid
exud
mononuclear
inflammatori
lymphocyt
seen
lung
patient
histori
long
exposur
immunotherapi
kind
paradox
immunolog
respons
influenza
infectionvaccin
immun
checkpoint
inhibitor
describ
data
regard
immun
checkpoint
inhibitor
risk
patient
present
rapid
evolut
respiratori
failur
nt
treat
invas
procedur
probabl
due
cancer
emphysema
histori
nt
know
treatment
steroid
routin
recommend
use
contrast
side
effect
immunotherapi
could
help
control
pneumon
patient
case
evid
import
multidisciplinari
approach
even
presenc
sever
outbreak
like
pandem
knowledg
underli
diseas
concomit
treatment
import
take
best
individu
therapeut
decis
